LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2026

Feb 12, 2026

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2026-02-02

Reporting Person: Avicenna Life Sci Master Fund LP (N/A)
Reporting Person: Avicenna Life Sci Master GP LLC (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1538462	Indirect

Footnotes

F1: These shares of common stock par value $0.001 per share (the "Common Stock") are directly held by Avicenna Life Sci Master Fund LP. The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

F2: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.